Member Info for lukedrywaller

thats not my opinion its off the update word for word

my favorite bit
Substantial near-term news flow anticipated.

CTA filing for AVA6000 pro-doxorubicin
• Dosing first patients in phase I clinical study of AVA6000 prodoxorubicin
• Initial read-out of AVA6000 phase I study
• AVA6000 phase I trial data
• Therapeutic license deals for Affimer/preCISION platforms
• Commercial partnerships/license deals for Affimer diagnostic products

Anticipated News Flow 2020-21
• Avacta ships Affimer reagents to Cytiva and Adeptrix for Affimer COVID-19 test
development
• Prototype Affimer COVID-19 test performance
• Partnerships with distributors and OEM partners for the Affimer COVID-19
antigen test
• Clinical validation of the Affimer COVID-19 antigen test and CE marking/FDA
approval for sale to healthcare professionals
• Regulatory approvals of Affimer COVID-19 self-test for sale direct to consumers
• First revenues from Affimer COVID-19 tests

ive got the pdf of buisness update and outlook from today

Progress Update
• Quantities of the Affimer binders to SARS-COV-2 spike protein are being manufactured by
Avacta to be provided to Cytiva (and others) in the next few days.
• Cytiva aims to develop prototype lateral flow tests over the next few weeks.
• The test will then be clinically validated using patient samples at sites in the UK initially.
• Avacta aims to have validated and CE marked the test for professional and consumer use as
soon as possible in the summer.
• Avacta has also announced a partnership with Adeptrix to develop a BAMSTM assay for
COVID-19 infection to be run on the existing hospital installed base of mass spectrometers.
• PCR testing will not be able to provide daily testing for millions of people
• A rapid point-of-care antigen test using saliva is ideal for mass screening of
populations for COVID 19 infection.
• Performance is critical: Avacta has the advantage of Affimer reagents that are
highly specific to the SARS-COV-2 spike protein.
• A COVID-19 antigen test strip is expected to cost ~$2 to manufacture, sell to
consumers for ~$30 and to large healthcare/corporate customers in bulk for
$15 per test. Avacta has initiated discussions with distributors and OEM
partners.

Anybody worried about the Sp dropping?, just imagine for a minute how the market will react when the news drops along these lines...
"Avacta are pleased to announce that Cytiva has been successful in developing an Affimer-based rapid test that will directly identify the Covid-19 virus and provide in-field test results in minutes"
"The test could be ideal for use in a variety of scenarios, such as:
An in-home test and monitoring
To identify if patients require further testing or treatment in a clinical setting
To verify if patients are ready for release from quarantine
To screen individuals prior to entering closed public venues such as cruise ships and airplanes"

all hypothetical of course :)

https://www.youtube.com/watch?v=mTnV6ZA7_ss

#AVCT ??Analysts predict billions of dollars in sales over the next few years for the sector. If the U.S. and Europe used 85 million tests by August 4 and 20 million in the U.S. through next winter, that is a $3 billion market, Cowen analysts estimated.
https://t.co/NQe2cP0SqE

https://twitter.com/Tweet_trader01/status/1252496607024689152?s=09

The potential here is mind boggling ..
A in-pocket accurate sylvia test within minutes
Oosh
Five pounds per share please

For those that didn't know
Myles was formerly Aimchaos who was in #BMN
from 1.40p - 48p
Hes knows his onions
If hes got 2 million shares in this, we can expect good things

https://www.share-talk.com/tag/aim-chaos/#gs.3gzias

https://twitter.com/brian_mistrot/status/1245779109889728512?s=09

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB

https://twitter.com/Tweet_trader01/status/1244710784602685440?s=09

https://twitter.com/AntMwah/status/1231631672430465029?s=09

And there it is ??

Need news this week

https://twitter.com/TheMoneySponge/status/1201194580772818944?s=19

Boom!

With the major news due, the sp could be many multiples higher than current, just looking at the asx listed peers, major re-rate to catch up in valuations to them.
- DFS
- Binding off-take agreements
- Mining license
- Project finance
If this was to follow walkabout then 18p would be a comparable number.